Head-to-head evidence
Atezolizumab vs Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-L1 · full Non-Small Cell Lung Cancer pipeline
Atezolizumab
Marketed by Roche
NCT02008227 · Phase 3 · completed
This large randomized, active-controlled Phase 3 trial (1225 patients) compared atezolizumab to docetaxel in advanced NSCLC. The primary endpoint was overall survival, a hard clinical endpoint, and it was met: median OS 13.8 months for atezolizumab vs 9.6 months for docetaxel, HR 0.73 (95% CI 0.62-0.87), p=0.0003. The trial was not blinded (open-label), so despite the robust randomized design and positive result, the evidence is graded moderate rather than strong.
Next expected readout: November 2026 · NCT04958811 (registry estimate)
Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
Marketed by Roche
NCT03735121 · Phase 3 · completed
This was a randomized, open-label, active-controlled phase 3 study comparing subcutaneous atezolizumab with the established IV formulation in previously treated NSCLC. The primary endpoints were pharmacokinetic measures (serum trough concentration and AUC) rather than clinical outcomes, and the non-inferiority comparisons were met for both. Because the study was open-label and the primary endpoints were surrogate PK measures, the evidence is limited despite the randomized design and adequate sample size.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Atezolizumab's landscape · Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)'s landscape